Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Medifast, Inc.NYSE: MED
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $55.05M fell 35.6% year over year, ahead of the -36.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 8.2% from the prior quarter. Over 3 fiscal years it compounded at -32.8% a year.
Context
- Selling, general & admin amounted to 75.0% of revenue in FY2025, up 1.7 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $189.5M (-34.5%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $55.05M-8.2% QoQ
- Last fiscal yearDec 2025
- $289.4M-34.5% YoY
- LTMMar 2026
- $258.94M-36.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -35.6% | -38.6% | -2.9 pp |
| 1 year | -34.5% | -34.5% | -0.0 pp |
| 3-year CAGR | -32.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 289.4M USD
- Year-over-year change
- -34.5%
- 4-year CAGR
- -24.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 289.4M | -34.5% |
| FY2024 | 2024-12-31 | 441.75M | -32.0% |
| FY2023 | 2023-12-31 | 649.45M | -32.0% |
| FY2022 | 2022-12-31 | 955.61M | +4.9% |
| FY2021 | 2021-12-31 | 911.36M | — |
Selling, General & Admin vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -36.5% is the 9th highest of 10, against a peer median of +2.1%.
- Selling, general & admin amounts to 74.8% of revenue for MED, versus a peer median of 41.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $352.3M USD | +2.1% | -5.0% | 58.3% | |
| LTM May 2026 | $319.44M USD | -9.3% | -3.0% | 32.6% | |
| LTM Mar 2026 | $258.94M USD | -36.5% | -32.8% | 74.8% | |
| LTM Feb 2026 | $179.2M USD | -1.4% | -6.1% | 53.7% | |
AIIORobo.ai Inc. | FY2025 | $157.64M USD | +68.5% | +85.7% | 16593.7% |
| LTM Mar 2026 | $104.83M USD | -6.2% | -3.1% | 41.5% | |
| FY2025 | HK$64.34M HKD | +16.7% | -28.0% | 14.0% | |
| LTM Jan 2026 | $47.27M USD | +5.9% | +24.0% | 16.4% | |
| LTM Dec 2025 | $45.51M USD | +12.1% | +9.8% | 5.9% | |
| LTM Mar 2026 | $41.16M USD | -37.0% | -7.1% | 46.0% | |
| Peer median (excluding MED) | — | +2.1% | -3.1% | 41.5% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.